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Abstract
Cellular transformation and cancer progression is accompanied by changes in the metabolic 
landscape. Master co-regulators of metabolism orchestrate the modulation of multiple metabolic 
pathways through transcriptional programs, and hence constitute a probabilistically parsimonious 
mechanism for general metabolic rewiring. Here we show that the transcriptional co-activator 
PGC1α suppresses prostate cancer progression and metastasis. A metabolic co-regulator data 
mining analysis unveiled that PGC1α is down-regulated in prostate cancer and associated to 
disease progression. Using genetically engineered mouse models and xenografts, we demonstrated 
that PGC1α opposes prostate cancer progression and metastasis. Mechanistically, the use of 
integrative metabolomics and transcriptomics revealed that PGC1α activates an Oestrogen-related 
receptor alpha (ERRα)-dependent transcriptional program to elicit a catabolic state and metastasis 
suppression. Importantly, a signature based on the PGC1α-ERRα pathway exhibited prognostic 
potential in prostate cancer, thus uncovering the relevance of monitoring and manipulating this 
pathway for prostate cancer stratification and treatment.
The metabolic switch in cancer encompasses a plethora of discrete enzymatic activities that 
must be coordinately altered in order to ensure the generation of biomass, reductive power 
and the remodelling of the microenvironment1-4. Despite the existence of mutations in 
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metabolic enzymes5, it is widely accepted that the main trigger for metabolic 
reprogramming is the alteration in cancer genes that remodel the signalling landscape2. 
Numerous reports provide evidence of the pathways regulating one or a few enzymes within 
a metabolic pathway in cancer. However, the means of coordinated regulation of complex 
metabolic networks remain poorly documented.
Master transcriptional co-regulators of metabolism control a variety of genes that are in 
charge of remodelling the metabolic landscape, and their impact in cellular and systemic 
physiology has been studied for decades. It is worth noting that these co-regulators, through 
their capacity to interact and regulate diverse transcription factors, exhibit a unique capacity 
to control complex and extensive transcriptional networks, making them ideal candidates to 
promote or oppose oncogenic metabolic programs.
The tumour suppressor PTEN is a negative regulator of cell growth, transformation and 
metabolism6-9. PTEN and its main downstream pathway, PI-3-Kinase, have been extensively 
implicated in prostate cancer (PCa) pathogenesis and progression10-12. This tumour 
suppressor is progressively lost through the progression of PCa, and complete loss of PTEN 
is predominant in advanced disease and metastasis8. Genetically engineered mouse models 
(GEMMs) recapitulate many of the features of PCa progression. However, the molecular and 
metabolic bases for PCa metastasis remain poorly understood13-16. Indeed, complete loss of 
PTEN in the mouse prostate does not result in metastasis11, in turn suggesting that 
additional critical events are required in this process.
In this study, we designed a bioinformatics analysis to interrogate multiple PCa datasets 
encompassing hundreds of well-annotated specimens. This approach allowed us to define a 
master regulator of PCa metabolism that is crucial for the progression of the disease. Our 
results identify the Peroxisome proliferator-activated receptor gamma co-activator 1 alpha 
(PGC1α) as a suppressor of PCa metastasis. This transcriptional co-activator exerts its 
function through the regulation of Oestrogen-related receptor alpha (ERRα) activity, in 
concordance with the activation of a catabolic program and the inhibition of PCa metastasis.
 Results
 A bioinformatics screen identifies PGC1A as metabolic co-regulator associated to 
prostate cancer progression
We approached the study of PCa metabolism applying criteria to ensure the selection of 
relevant master regulators that contribute to the metabolic switch. We focused on 
transcriptional co-regulators of metabolism17 that i) were consistently altered in several 
publicly available PCa datasets18-24, and ii) were associated with reduced time to recurrence 
and disease aggressiveness. We first evaluated the expression levels of the metabolic co-
regulators in a study comprising 150 PCa specimens and 29 non-pathological prostate 
tissues (or controls)22. The analysis revealed 10 co-regulators in the set of study with 
significant differential expression in PCa compared to non-neoplastic prostate tissue (Fig. 
1a, Supplementary Fig. 1A). We next extended this observation to four additional 
datasets18,21,23,24 in which there was available data for non-tumoural and PCa tissues. Only 
the alteration in PPARGC1A (PGC1A), PPARGC1B (PGC1B) and HDAC1 expression was 
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further confirmed in the majority or all sets (Fig. 1b, Supplementary Fig. 1B). Among 
these, PGC1A was the sole co-regulator with altered expression associated to Gleason score 
(Supplementary Fig. 1C, D) and DFS (Fig. 1c).
In order to rule out that cellular proliferation could contribute to the alteration of metabolic 
regulators, we carried out an additional analysis in which we compared the expression of 
PGC1A in PCa versus a benign hyper-proliferative condition (benign prostate hyperplasia or 
BPH). The results corroborated that the decrease in PGC1A expression is associated to a 
cancerous state rather than to a proliferative condition (Supplementary Fig. 1E).
We observed that the expression of PGC1A was progressively decreased from primary 
tumours to metastasis (Fig. 1d, Supplementary Fig. 1F). Strikingly, genomic analysis 
revealed shallow deletions of PGC1A exquisitely restricted to metastatic PCa 
specimens19-22,25 (Fig. 1e), in full agreement with the notion that there is a selective 
pressure to reduce the expression of this transcriptional co-activator as the disease 
progresses.
From our analysis, PGC1α emerges as the major master metabolic co-regulator altered in 
PCa, with an expression pattern reminiscent of a tumour suppressor.
 Pgc1a deletion in the murine prostate epithelium promotes prostate cancer metastasis
PGC1α has been widely studied in the context of systemic metabolism26, whereas its 
activity in cancer is just beginning to be understood27-33. To ascertain the role of PGC1α in 
PCa in vivo, we conditionally deleted this metabolic co-regulator in the prostate 
epithelium34, alone or in combination with loss of the tumour suppressor Pten11 (Fig. 2a-d, 
Supplementary Fig. 2A, B). Pgc1a deletion alone or in the context of Pten heterozygosity 
did not result in any differential tissue mass or histological alteration, which led us to 
conclude that it is not an initiating event (Fig. 2b, d). However, compound loss of both Pten 
and Pgc1a resulted in significantly larger prostate mass (Fig. 2c), together with a remarkable 
increase in the rate of invasive cancer (Fig. 2d). Histological analysis of the prostate 
revealed the existence of vascular invasion in double mutant mice (DKO), but not in Pten-
deleted (Pten KO) prostates (Supplementary Fig. 2C). PGC1α regulates the inflammatory 
response, which could influence and contribute to the phenotype observed35. However, we 
did not observe significant differences in the infiltration of polimorphonuclear netrophils 
(PMN) and lympho-plasmacytic infiltrates in our experimental settings (Supplementary 
Fig. 2D). PGC1α has been also shown to induce angiogenesis in coherence with the 
induction of VEGF-A expression36. Pgc1a status in our GEMM did not alter VEGF-A 
expression and microvessel density (Supplementary Fig. 2E, F). We therefore excluded the 
possibility that regulation of angiogenesis or inflammation downstream PGC1α could drive 
the phenotype characterised in this study.
PCa GEMMs faithfully recapitulate many of the features of the human disease37. A reduced 
number of mouse models with clinically relevant mutations show increased metastatic 
potential13-16. Strikingly, histopathological analysis of our mouse model in the context of 
Pten loss revealed that DKO mice - but not Pten KO counterparts - presented evidence of 
metastasis, which was estimated in 44% to lymph nodes (LN) and 20% to liver (Fig. 2e, f 
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and Supplementary Fig. 2G). Metastatic dissemination was in agreement with the 
observation of Pan-cytokeratin (PanCK) and Androgen Receptor (AR)-positive PCa cell 
deposits in the lymph nodes of DKO mice (Fig. 2g). Of note, 33% of Pten KO mice 
presented small groups of PanCK-positive cells in LN (without metastatic lesions) 
(Supplementary Fig. 2H), suggesting that even if these cells are able to reach the LN, they 
lack capacity to establish clinical metastasis. Interestingly, bone analysis revealed 
disseminated groups (but not clinical metastasis) of PanCK-positive cells in DKO but not in 
Pten KO mice (Supplementary Fig. 2I-K). Analysis of a small cohort of Ptenpc−/−; 
Pgc1apc+/− mice demonstrated that heterozygous loss of Pgc1a is sufficient to promote 
aggressiveness, vascular invasion and metastasis (Supplementary Fig. 2L-N). This 
observation supports the notion that single copy loss of PGC1A (as observed in metastatic 
human PCa specimens, Fig. 1e) could be a key contributing factor to the metastatic 
phenotype.
The cooperative effect observed in our mouse model between loss of Pten and Pgc1a was 
supported by the direct correlation of the two transcripts in patient specimens and the 
association of PGC1A down-regulation with PTEN genomic loss (TCGA provisional 
data19,20, Supplementary Fig. 2O).
In summary, our data in GEMMs and patient datasets formally demonstrates that the down-
regulation of PGC1α in PCa is an unprecedented causal event for the progression of the 
disease and its metastatic dissemination.
 PGC1α suppresses prostate cancer growth and metastasis
In order to characterize the prostate tumour suppressive activity of PGC1α, we first 
evaluated its expression level in well-established PCa cell lines38. Using previously reported 
PGC1α-positive and negative melanoma cells28, we could demonstrate that PCa cell lines 
lack detectable expression of the transcriptional co-activator at the protein level (Fig. 3a). In 
agreement with this notion, PGC1α-silencing in these cells failed to impact on the 
expression of its well-established targets39 (Supplementary Fig. 3A). Importantly, through 
the analysis of publicly available datasets22, we could demonstrate that the transcript levels 
of PGC1A in metastatic cell lines are comparable to those observed in human metastatic 
PCa specimens and vastly reduced compared to PGC1α-positive melanoma cells (Fig. 3a, 
Supplementary Fig. 3B). Despite our efforts to optimize the detection of the protein with 
different commercial antibodies, we could not identify an immunoreactive band that would 
correspond to PGC1α, in contrast with other reports40,41. Yet, we cannot rule out that in 
non-basal conditions, stimulation of other factors such as AR41 or AMPK40 could lead to the 
up-regulation and allow detection of PGC1α in PCa cells.
Due to the lack of PGC1α detection in PCa cellular systems, we aimed at reconstituting the 
expression of this gene to levels achievable in the cancer cell lines previously reported28. By 
means of lentiviral delivery of inducible Pgc1α and doxycycline titration, we reached 
expression levels of this protein in three PCa cell lines (AR-dependent - LnCaP - and 
independent - PC3 and DU145) equivalent to that observed in the PGC1α-expressing 
melanoma cell line MeWo (Fig. 3b, Supplementary Fig. 3C, D). Next, we evaluated the 
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cellular outcome of expressing PGC1α in PCa cell lines. Interestingly, expression of Pgc1α 
in this context resulted in a reduction in bi-dimensional and three-dimensional growth (Fig. 
3c, d, Supplementary Fig. E), cellular proliferation (Fig. 3e, Supplementary Fig. 3F) and 
cell cycle progression (Supplementary Fig. 3G). Of note, we excluded the possibility that 
doxycycline treatment could influence the result of the growth analysis (Supplementary 
Fig. 3H). The Pgc1α phenotype was recapitulated in vivo, where ectopic expression of this 
gene decreased tumour formation and growth (Fig. 3f, Supplementary Fig. 3I-K). In 
agreement with the GEMM data, we did not observe a contribution of angiogenesis to the 
phenotype (Supplementary Fig. 3L-N).
We observed in GEMMs that Pgc1a-loss resulted in metastatic dissemination (Fig. 2). We 
next sought to study whether Pgc1α expression could oppose a pre-existing metastatic 
phenotype. To this end, we carried out xenotransplant assays in immunocompromised mice 
using luciferase-expressing Pgc1α-inducible PC3 cells. Intra-cardiac injection of these cells 
(Fig. 3g) revealed that Pgc1α expression blunted metastatic growth in the lung, and led to a 
remarkable decrease in bone colonisation (Fig. 3h-i). As an additional approach, we sought 
to analyse metastatic tumour re-initiation capacity by means of local injection of PCa cells at 
the metastatic site. Since PCa exhibits osteotropic nature42, we carried out intra-tibial 
injection of cells and the appearance of tumour masses in the bone was monitored43 (Fig. 
3j). The results demonstrated that PGC1α exerts a potent anti-metastatic activity both in 
bone tumour mass and metastatic foci (Fig. 3k). These data provide evidence of the anti-
metastatic potential of PGC1α.
 PGC1α determines the oncogenic metabolic wiring in prostate cancer
PGC1α regulates gene expression through the interaction with diverse transcription 
factors26. In order to define the transcriptional program associated to the tumour suppressive 
activity of PGC1α, we performed gene expression profiling from Pgc1α-expressing vs. non-
expressing PC3 cells. We identified 174 probes with significantly altered signal encoding 
genes predominantly related to functions such as mitochondrial catabolic programs and 
energy-producing processes26,44 (Supplementary Table 1, Fig. 4a), which we validated by 
qRTPCR (Fig. 4b-d, Supplementary Fig. 4).
In order to demonstrate that the tumour suppressive activity of PGC1α was indeed 
accompanied by a global metabolic wiring, we carried out integrative metabolomics. We 
analysed cell line, xenograft and GEMM tissue extracts using liquid-chromatography high-
resolution mass spectrometry (LC-HRMS). LC-HRMS metabolomics and subsequent 
biochemical assays confirmed that oxidative processes such as fatty acid β-oxidation (Fig. 
5a-d, Supplementary Fig. 5A-C, Supplementary Table 2-5) and tricarboxylic acid cycle 
(TCA, Fig. 5e, Supplementary Fig. 5D) were increased in response to Pgc1α expression. In 
order to quantitatively define the use of glucose in the TCA cycle, we carried out stable 13C-
U6-Glucose isotope labelling. This experimental approach provided definitive evidence of 
the increased oxidation of glucose in the mitochondria in Pgc1α expressing cells (Fig. 5f). 
This metabolic wiring was consistent with elevated oxygen consumption (basal and ATP-
producing) and ATP levels upon Pgc1α expression (Fig. 5g-i, Supplementary Fig. 5E-I, 
Supplementary Tables S2-5).
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We next reasoned that over-activation of mitochondrial oxidative processes would lead to 
decreased anabolic routes. On the one hand, we monitored the incorporation of carbons 
from 13C-U6-Glucose into fatty acids (through the export of citrate from TCA to the 
cytoplasm45 and conversion to acetyl CoA that is used for de novo lipid synthesis). 
Interestingly, we found a significant decrease in 13C incorporation into palmitate (reflected 
as 13C carbon pairs) when Pgc1α was expressed (Fig. 5j, Supplementary Fig. 5J). On the 
other hand, we monitored lactate production as a readout of aerobic glycolysis or “the 
Warburg effect”2, which has been associated to the anabolic switch. As predicted, Pgc1α-
expressing cells exhibited reduced extracellular lactate levels (Supplementary Fig. 5K). Of 
note, lactate production and respiration were unaltered by doxycycline challenge in non-
transduced PC3 cells (Supplementary Fig. 5L, M). Taken together, our data provide a 
metabolic basis for the tumour suppressive potential of PGC1α in PCa, according to which 
this metabolic co-regulator controls the balance between catabolic and anabolic processes 
(Fig. 5k).
 An ERRα-dependent transcriptional program mediates the prostate tumour suppressive 
activity of PGC1α
We next aimed to identify the transcription factor that mediated the activity of PGC1α, and 
hence we performed a promoter enrichment analysis. The results revealed a predominant 
abundance in genes regulated by ERRα (Fig. 6a). We corroborated these results with Gene 
Set Enrichment Analysis (GSEA; Normalized Enrichment Score=2.02; Nominal p 
value=0.0109)46. This transcription factor controls a wide array of metabolic functions, from 
oxidative processes to mitochondrial biogenesis44. We have shown that PGC1α is indeed 
capable of regulating functions attributed to ERRα, such as mitochondrial oxidative 
metabolism (Fig. 4, 5 and Supplementary Fig. 4, 5). In addition, we observed that Pgc1a 
expression led to increased mitochondrial volume (Supplementary Fig. 6A). In order to 
ascertain to which extent the growth inhibitory and anti-metastatic activity of PGC1α 
required its ability to interact with ERRα, we took advantage of a mutant variant of the co-
activator (PGC1αL2L3M) that is unable to interact with this and other nuclear receptors46,47. 
The expression of PGC1αL2L3M in PC3 cells (Supplementary Fig. 6B) failed to up-regulate 
target genes, to reprogram oxidative metabolism, to inhibit cell growth, and, importantly, to 
suppress bone metastasis in intratibial xenografts (Fig. 6b-f, Supplementary Fig. 6C). To 
further discriminate between PGC1a functions that depend on ERRa or other nuclear 
receptors, we undertook a targeted silencing approach, and we transduced Pgc1α-inducible 
PC3 cells with an ERRα-targeting or a scramble shRNA (Supplementary Fig. 6D). In 
coherence with the L2L3M mutant data, ERRα silencing partially blunted the effects of 
Pgc1α on gene expression and cell growth (Fig. 6g, Supplementary Fig. 6H). In vivo, 
silencing of ERRα in the presence of the ectopically expressed transcriptional co-activator 
resulted in a significant increase in bone metastasis incidence from 40% (in Pgc1α-
expressing cells transduced with scramble shRNA) to full penetrance (Fig. 6h). Of note, the 
requirement of ERRα for the effect of PGC1α was recapitulated in vitro with a reverse 
agonist of the transcription factor, namely XCT79048 (Supplementary Fig. 6F-I).
It is worth noting that other metabolic pathways have been suggested to sustain the 
metastatic phenotype. Oxidative stress has been shown to limit metastatic potential in breast 
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cancer and melanoma29,49. PGC1α regulates the expression of antioxidant genes, while the 
enhancement of mitochondrial metabolism can lead to the production of reactive oxygen 
species (ROS)28,29,49 (Fig. 4b and Supplementary Table 1). We therefore tested whether 
ROS production was modified in our experimental settings and if it could contribute to the 
phenotype observed. Mitochondrial and cellular ROS production were not consistently 
altered by Pgc1α expression in vitro (Supplementary Fig. 6J). In addition, lipid 
peroxidation (which serves as readout of ROS production) was unaffected in our xenograft 
study (Supplementary Fig. 6K). These results are coherent with the inability of 
antioxidants to rescue the proliferative defect elicited by Pgc1α (Supplementary Fig. 6L).
Our data provides a molecular mechanism by which ERRα activation downstream PGC1α 
promotes a metabolic rewiring that suppresses PCa proliferation and metastasis.
 A PGC1α-ERRα transcriptional signature harbours prognostic potential
We have shown that reduced PGC1A expression in PCa exhibits prognostic potential (Fig. 
1c). Since our data demonstrates that transcriptional regulation downstream ERRα is key for 
the tumour suppressive activity of this co-activator, we reasoned that the association of 
PGC1α with aggressiveness and DFS should be recapitulated when monitoring ERRα target 
genes (Fig. 7a). We started the analysis from the list of genes positively regulated by PGC1α 
in our cellular system (153 genes, Fig. 7b). As predicted, the analysis in two independent 
patient datasets confirmed that the average signal of the PGC1α gene list was positively 
correlated with time to PCa recurrence (Fig. 7c). In addition, we observed a decrease in the 
expression of the aforementioned gene list associated to disease initiation and progression 
(Supplementary Fig. 7A). Importantly, comparable results were obtained when we 
performed the analysis with the subset of ERRα-target genes within the PGC1α gene set (73 
genes, Supplementary Table 6, Fig. 7b, d and Supplementary Fig. 7B). We next sought to 
curate the gene list in order to consolidate a prognostic PGC1α-ERRα gene set. We 
therefore focused on genes that exhibited a strong correlation with PGC1A in patient 
datasets. We selected genes that were significantly correlated with the co-activator (R>0.2; 
p<0.05) in at least 3 out of 5 studies. The results unveiled a PGC1α transcriptional signature 
in patients consisting of 17 genes, the majority of which i) were directly correlated with the 
transcriptional co-activator in the queried datasets, ii) exhibited decreased expression in PCa 
vs. BPH and iii) were further down-regulated in metastatic disease (Supplementary Table 
7, Supplementary Fig. 7C, D). Nearly 60% of these genes were regulated by ERRα (10 
genes out of 17) and were selected for further analysis as a PGC1α-ERRα curated gene set 
(Supplementary Table 7). The results revealed reduced PGC1α-ERRα curated gene set 
expression as the disease progressed (Fig. 7e). We next analysed the association of the 
PGC1α-ERRα curated gene set with disease recurrence. To this end, we compared patients 
harbouring primary tumours with signal values in the first quartile (Q1) versus the rest (Q2-
Q4). Patients with signature positive tumours exhibited reduced DFS in two independent 
datasets (Fig. 7f). A Hazard ratio (HR) of 4.2 (Taylor) and 17.8 (TCGA) was defined for 
signature-positive patients, while signature-negative individuals presented reduced risk of 
recurrence, with HR of 0.23 (Taylor) and 0.05 (TCGA). Furthermore, the frequency of 
patients with signature-positive signal values was absent or low in the normal prostate group 
and further increased in metastasis compared to primary tumours (Supplementary Fig. 7E). 
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Taken together, ERRα-regulated metabolic transcriptional program is associated to the 
activity of PGC1α in PCa. This interplay is conserved in patient specimens and defines a 
gene signature that harbours prognostic potential.
 Discussion
In this study we provide a comprehensive analysis of master transcriptional co-regulators of 
metabolism in PCa. Through the use of human data mining analysis, GEMMs and cellular 
systems, our study presents evidence demonstrating that PGC1α exerts a tumour suppressive 
activity opposing PCa metastasis. Interestingly, three out of ten significantly altered co-
regulators (PGC1A, PGC1B and NRIP1, Fig. 1a) in the Taylor22 PCa dataset (2 out of 3 
consistently altered throughout databases, Fig. 1b) converge in the regulation of a common 
transcriptional metabolic program, led by ERRα44 and that is associated to the phenotype 
observed in this study. These data strongly suggest that such pathway is of critical 
importance for the control of aggressiveness properties in PCa. Indeed, our results 
demonstrate that a gene set composed of ERRα target genes that are under the control of 
PGC1α expression 1) is progressively down-regulated in PCa and metastatic disease, and 2) 
presents prognostic potential for the identification of patients at risk of early recurrence.
The study of the tumour suppressive potential of Pgc1α in mouse models allowed us to 
characterise a clinically relevant PCa GEMM presenting enhanced metastatic dissemination. 
PGC1α is added to the short list of genetic events that drive metastasis in this model13-16, 
and the first to be explicitly linked to the regulation of the metabolic switch. Overall, our 
finding is of importance for the future study of the requirements for PCa metastasis and 
therefore for therapeutic purposes.
The sole alteration of PGC1α expression in PCa has profound impact on the oncogenic 
metabolic switch50. This data is in line with the reported activities of this protein in 
metabolism and mitochondrial biogenesis26. Of note, despite the widely accepted fact that 
the reported metabolic switch50 has comparable consequences in all cancer scenarios, the 
study of PGC1α in other tumour types has also revealed a selective pressure towards 
oxidative processes27-29. Previous work from others and us defined PGC1α signalling as a 
selective advantage for breast cancer and melanoma cells4,27-29,51. The contribution of this 
co-activator to cellular proliferation differs between tumour types and experimental systems, 
promoting growth in melanoma28 while irrelevant to breast cancer cells29. Interestingly, in 
breast circulating tumour cells, PGC1α expression supports metastatic capacity29. The 
molecular pathways regulating these diverse biological features converge in the activation of 
ERRα and Peroxisome proliferator-activated receptors (PPAR). While PPAR activation 
mediates the increase in fatty acid β-oxidation4, ERRα is responsible for the overall increase 
in oxidative metabolism and mitochondrial biogenesis44. Similarly, the activation of an 
antioxidant transcriptional program has been suggested to contribute to anoikis and cancer 
cell dissemination in a PGC1α-dependent and independent manner27,28,49,52. In PCa, 
however, we demonstrate that the oxidative metabolic program elicited by PGC1α prevents 
tumour growth and metastatic dissemination, in the absence of overt changes in ROS 
production, inflammatory response or angiogenic signals. These findings support the notion 
that the optimal metabolic wiring for tumour growth and metastasis might differ depending 
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on the tumour type, the mutational landscape of the tumour and, potentially, the 
microenvironment. This would lead to opposite activities of PGC1α depending on the cancer 
setting, from metastatic promoter29 to metastasis suppressor (as we demonstrate in the 
present work).
In summary, our study identifies PGC1α as a master regulator of PCa metabolism that 
opposes the dissemination of the disease. Therefore, a PGC1α-regulated ERRα-dependent 
transcriptional program might open new avenues in the identification of metabolic 
transcriptional signatures that can be exploited for patient stratification and the use of 
metabolism-modulatory therapies.
 Materials and Methods
 Reagents
3-[4-(2,4-Bis-trifluoromethylbenzyloxy)-3-methoxyphenyl]-2-cyano-N-(5-
trifluoromethyl-1,3,4-thiadiazol-2-yl)acrylamide (XCT 790), etomoxir (ETO), Doxycycline 
hyclate (Dox), oligomycin, N-acetyl-cysteine (NAC) and Manganese (III) tetrakis (4-benzoic 
acid)porphyrin chloride (MnTBAP) were purchased from Sigma.
 Cell culture
Human prostate carcinoma cell lines, LnCaP, DU145 and PC3 were purchased from 
Leibniz-Institut DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen 
GmbH, who provided authentication certificate. None of the cell lines used in this study 
were found in the database of commonly misidentified cell lines maintained by ICLAC and 
NCBI Biosample. Cells were transduced with a modified TRIPZ (Dharmacon) doxycycline 
inducible lentiviral construct in which the RFP and miR30 region was substituted by HA-
Flag-Pgc1a51 or HA-Flag-Pgc1aL2L3M 47. Lentiviral shRNA constructs targeting PGC1A 
(TRCN0000001166) and ESRRA (TRCN0000022180) where purchased in Sigma and a 
scramble shRNA (hairpin sequence: 
CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTG) was 
used as control. For ESRRA shRNAs, Puromycin resistance cassette was replaced by 
Hygromycin cassette from pLKO.1 Hygro (Addgene Ref. 24150) using BamHI and KpnI 
sites. Melanoma lines were kindly provided by Dr. Boyano53 and Dr. Buque and purchased 
from ATCC. Cell lines were routinely monitored for mycoplasma contamination and 
quarantined while treated if positive.
 Animals
All mouse experiments were carried out following the ethical guidelines established by the 
Biosafety and Welfare Committee at CIC bioGUNE and The Institutional Animal Care and 
Use Committee of IRB Barcelona. The procedures employed were carried out following the 
recommendations from AAALAC. Xenograft experiments were performed as previously 
described54, injecting 106 cells per condition in two flanks per mouse. PC3 TRIPZ-HA-
Pgc1a cells were injected in each flank of nude mice and 24 h post-injections mice were fed 
with chow or doxycycline diet (Research diets, D12100402). GEMM experiments were 
carried out as reported in a mixed background11,14,55,56 (where the founder colony was 
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cross-bred for at least three generations prior to the expansion of experimental cohorts in 
order to ensure and homogenous mixed background). The PtenloxP and Pgc1aloxP 
conditional knockout alleles have been described elsewhere11,34. Prostate epithelium 
specific deletion was effected by the Pb-Cre411. Mice were fasted for 6 h prior to tissue 
harvest (9 am-3 pm) in order to prevent metabolic alterations due to immediate food intake.
For intra-tibial and intra-cardiac injections BALB/c nude male mice (Harlan) of 9-11 weeks 
of age were used. Before the injections, PC3 Tripz-HA-Pgc1a (WT, L2L3M, shSC, 
shERRA) cell lines were pre-treated for 48h with PBS or doxycycline (0.5μg/ml). Mice 
injected with cells treated with doxycycline were also pre-treated for 48h with 1mg/ml of 
doxycycline in drinking water. After the injections this group of mice was left on continuous 
doxycycline treatment (1mg/ml in drinking water). Before the injections mice were 
anesthetized with mixture of Kethamine (80 mg/kg) and Xilacine (8 mg/kg). For intra-tibial 
injections, 1×104 cells were resuspended in final volume of 5 μl of cold PBS and injected as 
described previously57. For intra-cardiac injections 2×105 cells were resuspended in final 
volume of 100 μl of cold PBS and injected as described previously57. Upon the injections 
tumour development was followed on weekly basis by BLI using the IVIS-200 imaging 
system from Xenogen. Quantification of bioluminescent images was done with Living 
Image 2.60.1 software. the development of metastasis was confirmed by doing in vivo or ex 
vivo (upon necropsy) bioluminescent images of organs of interest (metastasis positivity in 
lesion incidence analysis was defined as tibias with luciferase signals greater than 50.000 
units). When comparing cell lines independently transduced with the luciferase-expressing 
vector (Fig. 6h), photon flux values per limb where presented as normalized signal 
(corrected by basal signal, obtained within 24 hours after injection): Normalized photon flux 
= [day 14 signal/day 0 signal] × 1000. For metastasis-free survival curves metastatic event 
was scored when measured value of bioluminescence bypasses 1/10 of the day 0 value.
 Patient samples
All samples were obtained from the Basque Biobank for research (BIOEF, Basurto 
University hospital) upon informed consent and with evaluation and approval from the 
corresponding ethics committee (CEIC code OHEUN11-12 and OHEUN14-14).
 Cellular, molecular and metabolic assays
Cell number quantification with crystal violet58 was performed as referenced.
Western blot was performed as previously described51. Antibodies used: PGC1α (H300; 
Santa Cruz Biotechnology sc-13067; dilution 1:1000); ERRα (E1G1J; Cell Signalling 
#13826; dilution 1:1000); β-Actin (clone AC-74; Sigma #A 5316; dilution 1:2000); GAPDH 
(clone 14C10; Cell Signalling #2218; dilution 1:1000); HSP90 (Cell Signalling; #4874; 
dilution 1:1000).
RNA was extracted using NucleoSpin® RNA isolation kit from Macherey-Nagel (ref: 
740955.240C). For patients and animal tissues a Trizol-based implementation of the 
NucleoSpin® RNA isolation kit protocol was used as reported59. For all cases, 1μg of total 
RNA was used for cDNA synthesis using qScript cDNA Supermix from Quanta (ref. 
95048). Quantitative Real Time PCR (qRTPCR) was performed as previously described51. 
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Universal Probe Library (Roche) primers and probes employed are detailed in 
Supplementary Table 8. β-ACTIN (Hs99999903_m1; Mm0607939_s1) and GAPDH 
(Hs02758991_g1, Mm99999915_g1) housekeeping assays from Applied Biosystems 
showed similar results (all qRTPCR data presented was normalized using GAPDH/Gapdh).
FAO was performed as previously described51. Lactate production was performed as 
referenced60 using Trinity Biotech lactate measurement kit.
Oxygen consumption rate (OCR) was measured with a XF24 extracellular flux analyser 
(Seahorse Bioscience)61. Briefly, 50.000 cells per well were seeded in a XF24 plate, and 
OCR measurements were normalized to cell number analysed by crystal violet. Cells were 
initially plated in 10% FBS DMEM media for 24 hours, and 1h before measurements, media 
was changed to DMEM serum and bicarbonate free, with glutamine and glucose (10mM). 
Mitochondrial stress test was carried out using the following concentrations of injected 
compound: Oligomycin (1μM).
For mitochondrial ATP assays, 50.000 PC3 and DU145 cells plated onto 13-mm coverslips 
and transfected with a mitochondrial targeted luciferase chimera (mtLuc). Cells were 
perfused in the luminometer at 37°C with KRB solution containing 25 μM luciferin and 1 
mM CaCl2 and supplemented with 5.5 mM glucose. Under these conditions, the light output 
of a coverslip of transfected cells was in the range of 5.000–20.000 cps for the luciferase 
construct vs. a background lower than 100 cps. Luminescence was entirely dependent on the 
presence of luciferin and was proportional to the perfused luciferin concentration between 
20 and 200 μM.
Mitochondrial morphology was assessed by using a cDNA encoding mitochondrial matrix-
targeted DsRed (mtDsRed). Cells were seeded onto 24-mm diameter coverslip (thickness 
between 0.16–0.19 mm) (Thermo Scientific) and 24 h later cells were transfected with 2μg 
mtDSred (Lipofectamine LTX reagent; Invitrogen). mtDsRed expression was assessed 36 h 
later. All the acquisitions were performed with a confocal Nikon Eclipse Ti system and 
fluorescent images were captured by using NisElements 3.2.
Lipid peroxidation based on MDA detection was assayed in xenograft samples following the 
manufacture instructions (MAK085 Sigma-Aldrich).
ROS production was determined by Mitosox and DCF staining as previously described62.
 Histopathological analysis
After euthanasia, histological evaluation of a Haematoxylin and eosin (H&E) stained section 
from formalin-fixed paraffin embedded tissues of the following organs was performed: 
prostate gland, lymph nodes, long bones from lower limbs and other solid organs such as 
lungs and liver.
Following the consensus reported by Ittmann et al.63, prostate gland alterations were 
classified into 4 categories: gland within normal limits; high grade prostatic intraepithelial 
neoplasia (HGPIN); HGPIN with focal micro-invasion; and invasive carcinoma. 
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Lymphovascular invasion was assessed in all cases were micro-invasion foci or invasive 
carcinoma were observed.
Lymph node (LN) metastasis and the presence of groups of PCa cells in bone marrow (BM) 
were determined after haematoxylin-eosin (H&E) staining (LN) and immunohistochemical 
identification of cytokeratin (CK) and androgen receptor (AR) -expressing cells using a pan-
CK rabbit polyclonal antibody (Dako, Carpinteria, CA) and AR rabbit polyclonal antibody 
(Santa Cruz Biotechnology, sc-816) (LN and BM). In the case of BM, cases were classified 
as “dissemination negative” when none or few scattered (less than 5) CK-expressing cells 
were identified and “dissemination positive” when more than 5 or small groups of these cells 
were observed.
To assess the inflammatory component in the prostate tissues we performed a semi-
quantitative analysis in the glandular and the stromal areas separately for each of the 
specimens. We first determined the type of inflammatory cell present in each tissue 
compartment: polymorphonuclear neutrophils versus lympho-plasmacytic infiltrates. Then 
we performed a quantification of these cells using the following score system: 0- no 
inflammatory cells, 1-few cells, 2-moderate amount of cells and 3-high amount of cells. 
Scores in between were also determined as 0.5, 1.5 and 2.5. If both types of cells were 
present in one compartment, we chose the highest as the final score.
Proliferation was assessed in paraffin embedded xenografts samples by using Ki67 antibody 
(MA5-14520, Thermo Scientific). Microvessel density was determined and quantified in 
GEMMs and xenograft samples by the immunodetection of CD31 (Rabbit anti-CD31; Ref. 
ab28364 Abcam).
 Metabolomics
LCHR-MS metabolomics and stable isotope 13C-U6-Glucose labelling was performed as 
reported64-66. Briefly, PC3 TRIPZ-HA-Flag-Pgc1a cells treated or untreated for 72h with 
0.5μg/ml doxycycline were plated at 500.000 cells/well in 6-well plates. For LCHR-MS 
metabolomics and grown maintaining the doxycycline regime for 42h before harvesting, 
while for stable isotope 13C-U6-Glucose labelling experiments, 24h after seeding cells were 
washed and exposed to media with serum, without glucose and pyruvate and supplemented 
2mM 13C-U6-Glucose. 16h after that, cells were washed and another 13C-U6-Glucose pulse 
was performed for 2h before harvesting.
 Transcriptomic analysis
For transcriptomic analysis in PC3 TRIPZ-HA-Flag-Pgc1α cells, Illumina whole genome -
HumanHT-12_V4.0 (DirHyb, nt) method was used as reported67.
Promoter enrichment analysis was assessed with the Transcription Factors (TFs) dataset 
from MSigDB (The Molecular Signature Database; http://www.broadinstitute.org/gsea/
msigdb/collections.jsp). TFs dataset contain genes that share a transcription factor-binding 
site defined in the TRANSFAC (version 7.4, http://www.gene-regulation.com/) database. 
Each of these gene set was annotated by a TRANSFAC record. A hypergeometric test was 
used to detect enriched dataset categories.
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The GSEA was performed using the GenePattern web tool from the Broad Institute (http://
genepattern.broadinstitute.org). The list of PGC1α upregulated genes ranked by their fold 
change was uploaded and analysed against a list of ERRα target genes46. The number of 
permutations carried out were 1000 and the threshold was 0.05.
 Bioinformatic analysis
Database normalization: all the datasets used for the data mining analysis were downloaded 
from GEO, and subjected to background correction, log2 transformation and quartile 
normalization. In the case of using a pre-processed dataset, this normalization was reviewed 
and corrected if required.
Frequency of alteration of metabolic co-regulators (Fig. 1 and Fig. S1A): expression levels 
of the selected co-regulators were obtained from the dataset reported by Taylor et al22. A 
matrix containing signal values and clinical information was prepared in order to ascertain 
the up- or down-regulation. We computed the relative expression of an individual gene and 
tumour to the expression distribution in a reference population (patients without prostate 
tumour or metastasis). The returned value indicates the number of standard deviations away 
from the mean of expression in the reference population (Z-score). Using a fold change of 
+2 and −2 as a threshold, we determined the number of samples from the cancer dataset that 
were up- or down-regulated. p-values were calculated by comparing the means of normal of 
cancerous biopsies.
Quartile analysis in DFS: Patients biopsies from primary tumours were organized into four 
quartiles according to the expression of the gene of interest in two datasets. The recurrence 
of the disease was selected as the event of interest. Kaplan-Meier estimator was used to 
perform the test as it takes into account right-censoring, which occurs if a patient withdraws 
from a study. On the plot, small vertical tick-marks indicate losses, where a patient's survival 
time has been right-censored. With this estimator we obtained a survival curve, a graphical 
representation of the occurrence of the event in the different groups, and a p-value that 
estimate the statistical power of the differences observed.
For PGC1A genomic analysis, data from prostate cancer patients with copy number 
alteration information in Taylor22, Grasso21 and Robinson25 et al. datasets was extracted 
from cbioportal.org. Percentage of shallow deletions of primary tumours and metastatic 
patients was calculated separately.
Correlation analysis: Pearson correlation test was applied to analyse the relationship 
between paired genes. From this analysis, Pearson's coefficient (R) indicates the existing 
linear correlation (dependence) between two variables X and Y, giving a value between +1 
and –1 (both included), where 1 is total positive correlation, 0 is no correlation, and –1 is 
total negative correlation. The p-value indicates the significance of this R coefficient.
 Statistics and Reproducibility
No statistical method was used to predetermine sample size. The experiments were not 
randomized. The investigators were not blinded to allocation during experiments and 
outcome assessment. Unless otherwise stated, data analysed by parametric tests is 
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represented by the mean ± s.e.m. of pooled experiments and median ± interquartile range for 
experiments analysed by non-parametric tests. n values represent the number of independent 
experiments performed, the number of individual mice or patient specimens. For each 
independent in vitro experiment, at least three technical replicates were used (exceptions: in 
western blot analysis technical replicates are presented, in untargeted metabolomics two 
technical replicates were used and for, 13C-U6-Glucose isotope labelling one technical 
replicate was used) and a minimum number of three experiments were done to ensure 
adequate statistical power. For data mining analysis, ANOVA test was used for multi-
component comparisons and Student T test for two component comparisons. In the in vitro 
experiments, normal distribution was confirmed or assumed (for n<5) and Student T test was 
applied for two component comparisons. For in vivo experiments, as well as for 
experimental analysis of human biopsies (from Basurto U. Hospital) a non-parametric 
Mann-Whitney exact test was used, without using approximate algorithms to avoid different 
outcomes of statistics packages68. To this end, we applied the formulas described69 for 
small-sized groups and Graphpad Prism for large-sized groups. In the statistical analyses 
involving fold changes, unequal variances were assumed. For contingency analysis, Fisher 
exact test as used for 2-group comparison (metastasis incidence) and Chi Square when 
analyzing more than 2 groups (analysis of PGC1α-ERRα signature frequency in PCa human 
specimens). The confidence level used for all the statistical analyses was of 95% (alpha 
value = 0.05). Two-tail statistical analysis was applied for experimental design without 
predicted result, and one-tail for validation or hypothesis-driven experiments.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. PGC1A is down-regulated in prostate cancer
a, Frequency of alterations (differences greater than 2-fold vs. mean expression of non-
tumoural biopsies) in the expression of 23 master co-regulators of metabolism in a cohort of 
150 PCa patients22. *, statistically different expression (p<0.05) of the indicated gene in PCa 
(n=150) vs. normal (n=29) patient specimens (according to Supplementary Fig. 1A). b, 
Gene expression levels of PGC1A, PGC1B and HDAC1 in up to four additional PCa 
datasets (N: normal; PCa: prostate cancer). Sample size: Tomlins (Normal=23; PCa=52); 
Grasso (Normal=12; PCa=76); Lapointe (Normal=9; PCa=17); Varambally (Normal=6; 
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PCa=13). c, Association of the indicated genes with disease-free survival (DFS) in two PCa 
datasets (Low: 1st quartile distribution; High: 4th quartile distribution) (Sample size: TCGA 
provisional data19,20, primary tumours n=240; Taylor22, primary tumours n=131). d, PGC1A 
expression in normal prostate (N), primary tumour (PT) and metastatic (Met) specimens in 
Taylor and Lapointe datasets18,22. Sample size: Taylor N=29, PT=131 and Met=19; Lapointe 
N=9, PT=13 and Met=4. e, Incidence of PGC1A shallow deletions in three independent 
datasets21,22,25. Points outlined by circles indicate statistical outliers (d). Error bars represent 
minimum and maximum values (b and d). p, p-value. Statistic test: two-tailed Student T test 
(a, b), Kaplan-Meier estimator (c, DFS) and ANOVA (d).
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Figure 2. Combined deletion of Pgc1a and Pten in the murine prostate epithelia results in 
prostate cancer progression and dissemination
a, Schematic representation of the genetic cross and the time of analysis. b-c, Comparison of 
anterior prostate lobe weights (when both anterior lobes were analysed, the average was 
calculated and represented) between genotypes (Ptenwt Pgc1awt n=10 mice; Ptenpc+/+ 
Pgc1apc−/− n=9 mice; Ptenpc+/− Pgc1apc+/+ n=6 mice; Ptenpc+/− Pgc1apc−/− n=12 mice; Pten
pc−/−
 Pgc1apc+/+ n=7 mice; Ptenpc−/− Pgc1apc−/− n=9 mice; pc, prostate-specific allelic 
changes; +, Wildtype allele; −, deleted allele; wt: any given genotype resulting in the lack of 
deletion of Pgc1a or Pten alleles). d, Histopathological characterization of the prostate 
(HGPIN: High-grade prostatic intraepithelial neoplasia) in the indicated genotypes (Ptenwt 
Pgc1awt n=10 mice; Ptenpc+/+ Pgc1apc−/− n=9 mice; Ptenpc+/− Pgc1apc+/+ n=6 mice; 
Ptenpc+/− Pgc1apc−/− n=12 mice; Pten pc−/− Pgc1apc+/+ n=7 mice; Ptenpc−/− Pgc1apc−/− n=12 
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mice; pc, prostate-specific allelic changes; +, Wildtype allele; −, deleted allele; wt: any given 
genotype resulting in the lack of deletion of Pgc1a or Pten alleles). e, Quantification of the 
frequency of metastatic lesions in lymph nodes (LN) and liver of Pten KO (5 mice) and 
DKO (9 mice) mice. f, Representative histological images (200X) of LN with (right panel) 
and without (left panel) metastasis in the indicated genotypes. g, Representative 
immunohistochemical detection (200X) of Pan-cytokeratin (PanCK) and androgen receptor 
(AR) positive cells in metastatic LN of DKO mice. DKO; Ptenpc−/−, Pgc1apc−/−. n.s.: not 
significant; **p<0.01. H&E: Haematoxylin-eosin. Error bars indicate median with 
interquartile range (b, c). Statistic test: two-tailed Mann Whitney U test (b, c).
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Figure 3. PGC1α exhibits tumour and metastasis suppressive activity in PCa cell lines
a, Analysis of PGC1α expression by qRT-PCR (top histogram) and western blot in a panel 
of prostate cancer cell lines (technical duplicates are shown), using melanoma cell lines as 
positive (MeWo) and negative (HT114, HS294T and A375) controls (n=3, independent 
experiments). b, Representative experiment of PGC1α expression in PC3, DU145 and 
LnCaP cell lines after treatment with 0.5 μg/ml doxycycline (Dox) (similar results were 
obtained in three independent experiments). c, Relative cell number quantification in Pgc1α 
expressing and non-expressing cells. Data is represented as cell number at day 6 relative to − 
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Dox cells (n=12 in PC3; n=7 in DU145; n=3 in LnCaP, independent experiments). d-e, 
Effect of Pgc1α expression on anchorage-independent growth (d; n=3, independent 
experiments) and BrdU incorporation (e; n=3, independent experiments) in PC3 cells. f, 
Evaluation of tumour formation in xenotransplantation experiments (n=7 mice; 2 injections 
per mouse). g, Schematic representation of metastasis assay through intra-cardiac injection. 
h-i, Evaluation of metastatic capacity of Pgc1α-expressing PC3 cells using intra-cardiac 
xenotransplant assays (n=8 mice for − Dox and n=6 mice for + Dox). Luciferase-dependent 
signal intensity (upper panels) and metastasis-free survival curves (lower panels) of PCa 
cells in lungs (h) and limbs (i) was monitored for up to 28 days. Representative luciferase 
images are presented referred to the quantification plots. In hind limb photon flux analysis, 
average signal from two limbs per mouse is presented. (i) and (ii) depict tibia photon flux 
images from specimens that are proximal to the median signal in − Dox and + Dox, 
respectively. j, Schematic representation of bone metastasis assay through intra-tibial 
injection. k, Evaluation of the metastatic capacity of Pgc1α-expressing PC3 cells using 
intra-tibial xenotransplant assays (n=7 mice) Photon flux quantification at 20 days (upper 
panel) and incidence of metastatic lesions at the end point (lower panel). Representative 
luciferase images are presented referred to the quantification plots. For photon flux analysis, 
average signal from two limbs per mouse is presented. For incidence analysis, mice with at 
least one limb yielding luciferase signal > 50.000 units were considered metastasis-positive. 
(i) and (ii) depict tibia photon flux images from specimens that are proximal to the median 
signal in − Dox and + Dox, respectively. + Dox: Pgc1α induced conditions; − Dox: Pgc1α 
non-expressing conditions. Error bars represent standard deviation of the mean (c), s.e.m. (d, 
e) or median with interquartile range (h-k). Statistic tests: two-tailed Student T test (c, d and 
e), one-tailed Mann-Whitney U test h, i and k (upper panels)), log-rank test (f, h and i (lower 
panels)) and Fisher's exact test (k, lower panels). p, p-value. *p < 0.05, **p < 0.01, ***p < 
0.001. Statistics source data for Fig. 3k are provided in Supplementary Table 9.
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Figure 4. PGC1α induces a metabolic transcriptional program
a, KEGG (Kyoto Encyclopaedia of Genes and Genomes) analysis of the transcriptional 
program regulated by PGC1α. Red dotted line indicates p=0.05. b-d, Validation of 
microarray by qRTPCR in PC3 TRIPZ-HA-Pgc1a cells (b, n=3 for TP53INP2, SOD2, NNT, 
GSTM4, ETFDH, GOT1, CLYBL, SUCLA2, MPC1, MPC2, ACAT1 and ACSL4; n=4 for 
ATP1B1, ISCU, SDHA, IDH3A and ACADM; independent experiments; data is normalised 
to − Dox condition, represented by a black dotted line), xenograft samples (c, − Dox n=11 
tumours; + Dox n=6 tumours) and prostate tissue samples from Pten KO and DKO mice (d, 
n=7 mice). Adj pvalue: adjusted p-value; +Dox: Pgc1α induced conditions; −Dox: Pgc1α 
non-expressing conditions; Pten KO: Ptenpc−/−, Pgc1apc+/+; DKO: Ptenpc−/−, Pgc1apc−/−. 
Error bars indicate s.e.m. (b) or median with interquartile range (c, d). Statistic tests: one-tail 
Student T test (b); one-tail Mann Whitney U test (c, d). *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 5. PGC1α induces a catabolic metabolic program
a-c, Untargeted LC-HRMS analysis of differential abundance in metabolites involved in 
fatty acid catabolism in Pgc1α-expressing PC3 cells (a, n=4, independent experiments), 
xenograft (b, − Dox n=8 tumours; + Dox n=4 tumours) and GEMM (c, Pten KO n=3 mice; 
DKO n=5 mice). d, Evaluation of the dehydrogenation of tritiated palmitate (readout of β-
oxidation) in PC3 cells upon Pgc1α expression (n=6, independent experiments). e, Effect of 
Pgc1α expression on the abundance TCA intermediates measured by LC-HRMS in PC3 
cells (n=4, independent experiments). f, Effect of Pgc1α expression on tricarboxylic acid 
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cycle (TCA) intermediates (mass isotopomer abundance) after stable 13C-U6-Glucose 
labelling in PC3 cells (n=3, independent experiments). g, Oxygen consumption rate (OCR) 
in PC3 Pgc1α expressing cells (n=7, independent experiments). h, Basal mitochondrial ATP 
production in PC3 cells upon Pgc1α expression (n=20 for − Dox and n=10 for + Dox 
conditions, independent experiments). i, LC-HRMS quantification of ATP abundance in 
xenografts (left panel, − Dox n=8 tumours; + Dox n=4 tumours) and GEMM (right panel, 
Pten KO n=3 mice; DKO n=5 mice). j, Effect of Pgc1α expression on palmitate paired mass 
isotopomer abundance after stable 13C-U6-Glucose labelling in PC3 cells (n=3, independent 
experiments). k, Schematic representation of the main findings of the study. Pyr: pyruvate; 
AcCoA; acetyl CoA; OAA: oxaloacetate; Mal: malate; Fum: fumarate; Succ: succinate; Cit: 
citrate; ETC: electron transport chain; TCA: tricarboxylic acid cycle; FA: fatty acids. a.u.: 
arbitrary units; Mal: malate; Fum: fumarate; OAA: oxaloacetate. Error bars indicate s.e.m. 
(a, d, e, f, h, j), standard deviation of the mean (g) or median with interquartile range (b, c, i). 
Statistic tests: two-tail Student T test (a, d, e, f, g, h, j); one-tail Mann Whitney U test (b, c, 
i). *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 6. An ERRα-dependent transcriptional program mediates the tumour suppressive 
activity of PGC1α
a, Promoter enrichment analysis of the PGC1α transcriptional program. Red dotted line 
indicates p=0.05. b-d, Effect of Pgc1αWT or Pgc1αL2L3M induction on the expression of 
indicated genes (b, qRTPCR; n=8 for IDH3A; n=4 for ATP1B1; n=3 for ACAT1, ISCU, 
GOT1 and ACADM genes, independent experiments; data is normalised to each − Dox 
condition, represented by a black dotted line), relative cell number by crystal violet (c, n=7, 
independent experiments) and oxygen consumption rate (d, OCR, n=5, independent 
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experiments). e-f, Evaluation of the metastatic capacity of PC3 Pgc1αWT (upper panels) or 
PC3 Pgc1αL2L3M (lower panels) expressing cells using intra-tibial xenotransplant assays (e, 
photon flux quantification, WT, n=6 mice and L2L3M, n=7 mice, 2 hind limb per mice; f, 
incidence of metastatic lesions presented as histograms). Representative luciferase images 
are presented referred to the quantification plots. For photon flux analysis, average signal 
from two limbs per mouse is presented. For incidence analysis, mice with at least one limb 
yielding luciferase signal > 50.000 units were considered metastasis-positive. (i) and (ii) 
depict tibia photon flux images from specimens that are proximal to the median signal in − 
Dox and + Dox, respectively. g, Relative cell number quantification upon ERRα silencing in 
PC3 Pgc1α expressing cells. Data is represented as cell number at day 4 relative to − Dox 
cells (n=3, independent experiments). h, Evaluation of metastatic capacity of Pgc1α-
expressing PC3 cells transduced with shSC or shERRα using intra-tibial implantation for 14 
days (n=8 mice; 2 injections per mice; incidence of metastatic lesions presented as 
histograms). Representative luciferase images are presented referred to the quantification 
plots. For photon flux analysis (left panel), average signal from two limbs per mouse is 
presented. For incidence analysis (right panel), mice with at least one limb yielding 
luciferase signal > 50.000 units were considered metastasis-positive. Adj. p-value: adjusted 
p-value. +Dox: Pgc1α induced conditions; −Dox: Pgc1α non-expressing conditions. Min: 
minimum. Max: maximum. n.s.: not significant. Error bars represent s.e.m. (b, c, d, g) or 
median with interquartile range (e, h). Statistic tests: one-tailed Student T test (b, c, d, g); 
one-tailed Mann-Whitney U test (e, h (left panel)); Fisher exact test (f, h (right panel)). */$ p 
< 0.05, **/$$ p < 0.01, ***/$$$ p < 0.001. Asterisks indicate statistical difference between – 
Dox and + Dox conditions and dollar symbol between Pgc1αWT and Pgc1αL2L3M or shSC 
and shERRα. Statistics source data for Fig. 6e,h are provided in Supplementary Table 9.
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Figure 7. The PGC1α transcriptional program is associated with prostate cancer recurrence
a, Schematic summary of the ERRα-dependent regulation of PGC1α transcriptional 
metabolic program, and its association with PCa progression. Dashed PGC1α box (pink) 
represents a decrease in abundance. b, Venn diagram showing the distribution of PGC1α 
target genes, ERRα target genes and genes correlated with PGC1A expression in PCa 
patient specimens (from Supplementary Table 7). c-d, Correlation between time to 
recurrence and the average signal of the genes within the PGC1α-upregulated gene set (c) or 
the PGC1α-dependent ERRα-upregulated gene set (d) in the indicated datasets19,20,22 
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(Taylor n=27; TCGA provisional dataset n=8). Each dot corresponds to an individual patient 
specimen. e, Representation of the average signal of the genes within the “PGC1α-ERRα 
curated gene set” (Supplementary Table 7) in normal (N; Taylor n=29 and Grasso n=12), 
primary tumours (PT; Taylor n=131 and Grasso n=49) and metastasis (Met; Taylor n=19 and 
Grasso n=27), in two independent datasets21,22. Each dot corresponds to an individual 
patient specimen. f, Association of the “PGC1α-ERRα signature” with disease-free survival 
(DFS) in the indicated patient datasets19,20,22 (Taylor n=131; TCGA provisional dataset 
n=240). Q1 indicates patients with signature signal within the first quartile of primary 
tumours in the corresponding dataset. Error bars indicate s.e.m. Statistic test: Pearson's 
coefficient (R) (c and d), ANOVA (e) and Kaplan-Meier estimator (f).
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